Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 17 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide may be a potential treatment. METHODS: We conducted two phase 3, double-blind, randomized, controlled trials involving adults with moderate-to-severe obstructive sleep apnea and obesity. Participants who were not receiving treatment with positive airway pressure (PAP) at baseline were enrolled in trial 1, and those who were receiving PAP therapy at baseline were enrolled in trial 2. The participants were assigned in a 1:1 ratio to receive either the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks. The primary end point was the change in the apnea-hypopnea index (AHI, the number of apneas and hypopneas during an hour of sleep) from baseline. Key multiplicity-controlled secondary end points included the percent change in AHI and body weight and changes in hypoxic burden, patient-reported sleep impairment and disturbance, high-sensitivity C-reactive protein (hsCRP) concentration, and systolic blood pressure. RESULTS: At baseline, the mean AHI was 51.5 events per hour in trial 1 and 49.5 events per hour in trial 2, and the mean body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) was 39.1 and 38.7, respectively. In trial 1, the mean change in AHI at week 52 was -25.3 events per hour (95% confidence interval [CI], -29.3 to -21.2) with tirzepatide and -5.3 events per hour (95% CI, -9.4 to -1.1) with placebo, for an estimated treatment difference of -20.0 events per hour (95% CI, -25.8 to -14.2) (P<0.001). In trial 2, the mean change in AHI at week 52 was -29.3 events per hour (95% CI, -33.2 to -25.4) with tirzepatide and -5.5 events per hour (95% CI, -9.9 to -1.2) with placebo, for an estimated treatment difference of -23.8 events per hour (95% CI, -29.6 to -17.9) (P<0.001). Significant improvements in the measurements for all prespecified key secondary end points were observed with tirzepatide as compared with placebo. The most frequently reported adverse events with tirzepatide were gastrointestinal in nature and mostly mild to moderate in severity. CONCLUSIONS: Among persons with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes. (Funded by Eli Lilly; SURMOUNT-OSA ClinicalTrials.gov number, NCT05412004.).
Overview
CoChat Summary
## TL;DR
In two 52-week phase 3 randomized controlled trials of adults with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide improved apnea-hypopnea index (AHI) and multiple secondary outcomes versus placebo. The paper concludes that tirzepatide reduced sleep-disordered breathing, body weight, hypoxic burden, hsCRP, systolic blood pressure, and improved sleep-related patient-reported outcomes.
## Key findings
- In trial 1, the mean change in AHI at week 52 was -25.3 events/hour with tirzepatide versus -5.3 events/hour with placebo; the estimated treatment difference was -20.0 events/hour (95% CI, -25.8 to -14.2; P<0.001).
- In trial 2, the mean change in AHI at week 52 was -29.3 events/hour with tirzepatide versus -5.5 events/hour with placebo; the estimated treatment difference was -23.8 events/hour (95% CI, -29.6 to -17.9; P<0.001).
- In the pooled analysis, participants receiving tirzepatide had significant reductions in PROMIS-SRI and PROMIS-SD T scores, and both trials showed significant reductions in body weight, systolic blood pressure, and hsCRP concentrations.
- The paper states that the most frequently reported adverse events with tirzepatide were gastrointestinal and generally mild-to-moderate; adverse events occurred in 79.8% vs 76.7% of participants in trial 1 and 83.2% vs 72.8% in trial 2 (tirzepatide vs placebo).
## Methods
- Two 52-week, phase 3, multicenter, parallel-group, double-blind, randomized, controlled trials were conducted at 60 sites across nine countries.
- Adults with moderate-to-severe obstructive sleep apnea (AHI ≥15 events/hour) and obesity (BMI ≥30; ≥27 in Japan) were enrolled; trial 1 included participants unable or unwilling to use PAP, and trial 2 included participants using PAP for at least 3 consecutive months and planning to continue.
- Participants were randomized 1:1 to weekly tirzepatide (10 mg or 15 mg maximum tolerated dose) or placebo; the primary endpoint was change in AHI from baseline, with key secondary endpoints including AHI percent change, body weight, hypoxic burden, hsCRP, patient-reported sleep outcomes, and systolic blood pressure. Analyses used ANCOVA and logistic regression, with multiplicity control via a graphical testing procedure.
## Limitations
- The paper states that the shorter duration of the trials does not support assessment of long-term cardiovascular outcomes.
- The trials excluded participants without obesity and did not assess people with overweight or normal BMI.
- The trials were not designed to test whether results differed by baseline symptoms, and trial 2 was not designed to assess PAP adherence effects; also, the minimum clinically important changes for PROMIS-SRI and PROMIS-SD were not established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 0 Not valid · 6 Not checked · 57 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Excess adiposity is a major reversible etiologic risk factor for obstructive sleep apnea and its complications. 8,9”
What the sources say
- Supportedcites [8] 8. Hudgel DW, Patel SR, Ahasic AM, et al. The role of weight management in the treatment of adult obstructive sleep apnea: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2018;198(6):e70-e87. [PubMed: 30215551] source
The Introduction says weight gain is linked to the development and worsening of OSA and that obesity aggravates its metabolic and cardiovascular comorbidities. “Putting It All Together” reports that weight loss consistently improves OSA severity and may improve associated health outcomes, supporting reversibility. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [9] 9. Morgenthaler TI, Kapen S, Lee-Chiong T, et al. Practice parameters for the medical therapy of obstructive sleep apnea. Sleep 2006;29:1031-5. [PubMed: 16944671] source
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This level of weight reduction has been difficult to accomplish with lifestyle intervention alone. 35”
What the sources say
- Partly supportedcites [35] 35. Dombrowski SU, Knittle K, Avenell A, Araújo-Soares V, Sniehotta FF. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ 2014;348:g2646. [PubMed: 25134100] sourceExperimental — accuracy not yet measured
The Introduction says few people maintain weight loss over the long term, and the Behavioural/lifestyle v control section reports a modest mean difference of −1.56 kg at 12 months. This supports the general difficulty of sustaining weight loss with lifestyle intervention, but the claim does not specify what “this level” is, so the paper cannot verify that particular level. (LLM, conf=0.78)
- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The potential issue of PAP confounding of the PROMIS outcomes in trial 2 was minimized by a 7-day PAP washout period. 22”
What the sources say
- Partly supportedcites [22] 22. Schwarz EI, Stradling JR, Kohler M. Physiological consequences of CPAP therapy withdrawal in patients with obstructive sleep apnoea-an opportunity for an efficient experimental model. J Thorac Dis 2018;10:Suppl 1:S24-S32. [PubMed: 29445525] sourceExperimental — accuracy not yet measured
The Physiological effects of CPAP withdrawal section reports that OSA recurred and subjective sleepiness increased one week after CPAP withdrawal, supporting the rationale for a washout. It does not assess PROMIS outcomes or establish that seven days minimized PAP confounding in trial 2; sleepiness continued to increase at two weeks. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The safety profile of tirzepatide was consistent with that observed in previous trials. 14,3739”
What the sources say
- Not checked — no full text of the sourcecites [14] 14. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205-16. [PubMed: 35658024] source
- Supportedcites [37] 37. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebocontrolled, phase 3 trial. Lancet 2023;402:613-26. [PubMed: 37385275] source
The Discussion explicitly states that tirzepatide’s safety profile was consistent with previous findings in the SURMOUNT-1 and SURPASS trials. The Safety section also describes the adverse events observed in this trial. (LLM, conf=0.95)
- Supportedcites [38] 38. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med 2023;29:2909-18. [PubMed: 37840095] source
The Discussion explicitly states that tirzepatide’s safety profile in this trial was consistent with findings from previous tirzepatide trials. It also notes modestly higher rates of gastrointestinal adverse events and treatment discontinuation than in the tirzepatide 15 mg group in SURMOUNT-1; that qualification does not negate the overall comparison. (LLM, conf=0.95)
- Partly supportedcites [39] 39. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38-48. [PubMed: 38078870] sourceExperimental — accuracy not yet measured
The Results (Adverse Events and Tolerability; page unavailable) describe tirzepatide’s safety findings, including gastrointestinal events and serious adverse events. The passages do not compare that safety profile with previous trials, so the claimed consistency with earlier findings is not established by our copy. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were five cases of severe or serious depressive disorder or suicidal ideation or behavior events across both trials (two with tirzepatide and three with placebo).”
plainn = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
29 more claims
Create a free account to see all 77 claims and every source verdict.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 31
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, some studies were designed for other purposes17,18,30,41–44—for example, prevention of CVD or T2D.”
From A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults (2025) · cites this paper as [43]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These medications allow most patients to achieve clinically meaningful weight loss, improve severity of OSA, and improve cardiometabolic comorbidities.13,14”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These medications allow most patients to achieve clinically meaningful weight loss, improve severity of OSA, and improve cardiometabolic comorbidities.13,14”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These medications allow most patients to achieve clinically meaningful weight loss, improve severity of OSA, and improve cardiometabolic comorbidities.13,14”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SURMOUNT-OSA trial reported that tirzepatide reduced the apnea-hypopnea index by 25% to 29% over 52 weeks in individuals with obesity and moderate to severe OSA, compared with a reduction of 5.3% to 5.5% in the placebo group, regardless of the use of positive airway pressure therapy (19).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Benjafield, A. V., Ayas, N. T., Eastwood, P. R., Heinzer, R., Ip, M. S. M., Morrell, M. J., Nunez, C. M., Patel, S. R., Penzel, T., Pépin, J.-L., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30198-5 · Cited by 4,326
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationAdult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine, Epstein, L. J., Kristo, D., Strollo, P. J., Friedman, N., Malhotra, A., Patil, S. P., Ramar, K., Rogers, R., Schwab, R. J., et al. (2009) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27497 · Cited by 3,360
Self-citationCPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea
McEvoy, R. D., Antic, N. A., Heeley, E., Luo, Y., Ou, Q., Zhang, X., Mediano, O., Chen, R., Drager, L. F., Liu, Z., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606599 · Cited by 2,101
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Adult obstructive sleep apnoea
Jordan, A. S., McSharry, D. G., & Malhotra, A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60734-5 · Cited by 1,735
Self-citationJavaheri, S., Barbe, F., Campos-Rodriguez, F., Dempsey, J. A., Khayat, R., Javaheri, S., Malhotra, A., Martinez-Garcia, M. A., Mehra, R., Pack, A. I., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.069 · Cited by 1,434
Self-citationYeghiazarians, Y., Jneid, H., Tietjens, J. R., Redline, S., Brown, D. L., El-Sherif, N., Mehra, R., Bozkurt, B., Ndumele, C. E., Somers, V. K., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000988 · Cited by 1,431
Self-citationRamar, K., Dort, L. C., Katz, S. G., Lettieri, C. J., Harrod, C. G., Thomas, S. M., & Chervin, R. D. (2015) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.4858 · Cited by 915
Azarbarzin, A., Sands, S. A., Stone, K. L., Taranto-Montemurro, L., Messineo, L., Terrill, P. I., Ancoli-Israel, S., Ensrud, K., Purcell, S., White, D. P., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy624 · Cited by 893
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA · doi:10.1001/jama.2023.24945 · Cited by 860
Self-citationDombrowski, S. U., Knittle, K., Avenell, A., Araujo-Soares, V., & Sniehotta, F. F. (2014) · BMJ · doi:10.1136/bmj.g2646 · Cited by 816
Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01200-x · Cited by 792
Self-citationPeker, Y., Glantz, H., Eulenburg, C., Wegscheider, K., Herlitz, J., & Thunström, E. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0088oc · Cited by 756
Patil, S. P., Ayappa, I. A., Caples, S. M., Kimoff, R. J., Patel, S. R., & Harrod, C. G. (2019) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.7638 · Cited by 721
Obstructive Sleep Apnea in Adults
Veasey, S. C., & Rosen, I. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmcp1816152 · Cited by 615
(2009) · PubMed · Cited by 582
Sánchez-de-la-Torre, M., Sánchez-de-la-Torre, A., Bertran, S., Abad, J., Duran-Cantolla, J., Cabriada, V., Mediano, O., Masdeu, M. J., Alonso, M. L., Masa, J. F., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30271-1 · Cited by 522
Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02597-w · Cited by 442
Self-citationA graphical approach to sequentially rejective multiple test procedures
Bretz, F., Maurer, W., Brannath, W., & Posch, M. (2009) · Statistics in Medicine · doi:10.1002/sim.3495 · Cited by 420
Practice Parameters for the Medical Therapy of Obstructive Sleep Apnea
Standards of Practice Committee of the American Academy of Sleep Medicine, Morgenthaler, T. I., Kapen, S., Lee-Chiong, T., Alessi, C., Boehlecke, B., Brown, T., Coleman, J., Friedman, L., Kapur, V., et al. (2006) · Sleep · doi:10.1093/sleep/29.8.1031 · Cited by 299
Lin, H., Friedman, M., Chang, H., & Gurpinar, B. (2008) · The Laryngoscope · doi:10.1097/mlg.0b013e31816422ea · Cited by 289
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161356.esgl · Cited by 283
Hudgel, D. W., Patel, S. R., Ahasic, A. M., Bartlett, S. J., Bessesen, D. H., Coaker, M. A., Fiander, P. M., Grunstein, R. R., Gurubhagavatula, I., Kapur, V. K., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1326st · Cited by 266
Self-citationThe Sleep Apnea-Specific Hypoxic Burden Predicts Incident Heart Failure
Azarbarzin, A., Sands, S. A., Taranto-Montemurro, L., Vena, D., Sofer, T., Kim, S.-W., Stone, K. L., White, D. P., Wellman, A., & Redline, S. (2020) · Chest · doi:10.1016/j.chest.2020.03.053 · Cited by 230
Self-citationRamar, K., Dort, L. C., Katz, S. G., Lettieri, C. J., Harrod, C. G., Thomas, S. M., & Chervin, R. D. (2015) · Journal of Dental Sleep Medicine · doi:10.15331/jdsm.4868 · Cited by 169
Wilson, J. M., Lin, Y., Luo, M. J., Considine, G., Cox, A. L., Bowsman, L. M., Robins, D. A., Haupt, A., Duffin, K. L., & Ruotolo, G. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14553 · Cited by 149
Malhotra, A., Bednařík, J., Chakladar, S., Dunn, J. P., Weaver, T. E., Grunstein, R. R., Fietze, I., Redline, S. S., Azarbarzin, A., Sands, S. A., et al. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2024.107516 · Cited by 124
Self-citationEuropean Respiratory Society statement on sleep apnoea, sleepiness and driving risk
Bonsignore, M. R., Randerath, W., Schiza, S., Verbraecken, J., Elliott, M. W., Riha, R., Barbe, F., Bouloukaki, I., Castrogiovanni, A., Deleanu, O., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.01272-2020 · Cited by 84
Zhang, Y., Wang, W., Yang, C., Shen, J., Shi, M., & Wang, B. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3573-5 · Cited by 40
Schwarz, E. I., Stradling, J. R., & Kohler, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.142 · Cited by 40
Severity of OSAS, CPAP and cardiovascular events: A follow‐up study
Baratta, F., Pastori, D., Fabiani, M., Fabiani, V., Ceci, F., Lillo, R., Lolli, V., Brunori, M., Pannitteri, G., Cravotto, E., et al. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.12908 · Cited by 40
Mandibular Advancement Devices for OSA: An Alternative to CPAP?
Francis, C. E., & Quinnell, T. (2021) · Pulmonary Therapy · doi:10.1007/s41030-020-00137-2 · Cited by 37
Donovan, L. M., Yu, L., Bertisch, S. M., Buysse, D. J., Rueschman, M., & Patel, S. R. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.11.011 · Cited by 28
Heinzer, R. C., & Eckert, D. J. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30351-0 · Cited by 24
Wadden, T. A., Chao, A. M., Machineni, S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02883-1 · Cited by 21
Patil, S. P., Ayappa, I. A., Caples, S. M., Kimoff, R. J., Patel, S. R., & Harrod, C. G. (2019) · SLEEP · doi:10.1093/sleep/zsz067.518 · Cited by 14
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/s-0044-1785403 · Cited by 13
Self-citationVandemeulebroecke, M., Häring, D. A., Hua, E., Wei, X., & Xi, D. (2024) · Clinical Trials · doi:10.1177/17407745231214382 · Cited by 2
0572 Weight reduction and the impact on apnea-hypopnea index: a meta-analysis
Malhotra, A., Curtis, A., Dunn, J., Bunck, M. C., & Bednarik, J. (2023) · SLEEP · doi:10.1093/sleep/zsad077.0572 · Cited by 2
Self-citationMalhotra, A., Bednarik, J., Chakladar, S., et al. (2024) · doi:10.2139/ssrn.4710000
Self-citation
Cited by
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2416394 · Cited by 634
Self-citationAmerican Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Eichorst, B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s005 · Cited by 305
Writing Committee Members*, Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., et al. (2025) · Hypertension · doi:10.1161/hyp.0000000000000249 · Cited by 310
Diabetes mellitus—Progress and opportunities in the evolving epidemic
Abel, E. D., Gloyn, A. L., Evans-Molina, C., Joseph, J. J., Misra, S., Pajvani, U. B., Simcox, J., Susztak, K., & Drucker, D. J. (2024) · Cell · doi:10.1016/j.cell.2024.06.029 · Cited by 292
Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.05.007 · Cited by 280
Metadata
- Authors
- Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., Bunck, M. C., & Bednarik, J.
- Affiliations
- Brigham and Women's Hospital (US)
- From the University of California, San Diego, La Jolla (A.M.); Woolcock Institute of Medical Research, Macquarie University, Royal Prince Alfred Hospital, and the University of Sydney — all in Sydney (R.R.G.); the Center of Sleep Medicine, Charité University Hospital Berlin, Berlin (I.F.); the College of Nursing, University of Illinois Chicago, Chicago (T.E.W.); the School of Nursing (T.E.W.) and Perelman School of Medicine (R.J.S.), University of Pennsylvania, Philadelphia; the Division of Sleep and Circadian Disorders, Brigham and Women’s Hospital, and Harvard Medical School — both in Boston (S.R., A.A., S.A.S.); and Eli Lilly, Indianapolis (J.P.D., S.C., M.C.B., J.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-03
- Volume
- 391
- Issue
- 13
- Pages
- 1193-1205
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11598664
- OpenAlex
- W4399907994
- Cited by
- 871
- References
- 39
- Citations by year
- 2026: 410 · 2025: 379 · 2024: 80
- FWCI
- 245.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Apelin-related biomedical research
- Keywords
- tirzepatide, obstructive sleep apnea, obesity, GLP-1 receptor agonists, GIP receptor agonist, apnea-hypopnea index, weight loss, positive airway pressure, hypoxic burden, sleep disorders, C-reactive protein, systolic blood pressure, cardiovascular risk, anti-obesity drugs, obesity-related sleep apnea, body mass index
- MeSH terms
- Sleep Quality, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Adult, Hypoxia, Blood Pressure, Body Weight, C-Reactive Protein, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Humans, Male, Middle Aged, Obesity, Severity of Illness Index, Treatment Outcome, Sleep Apnea, Obstructive, Maximum Tolerated Dose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.